Impact of interval from primary cytoreductive surgery to initiation of adjuvant chemotherapy in advanced epithelial ovarian cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Impact of interval from primary cytoreductive surgery to initiation of adjuvant chemotherapy in advanced epithelial ovarian cancer

Published:2018-09-19 Issue:3 Volume:143 Page:325-332
ISSN:0020-7292
Container-title:International Journal of Gynecology & Obstetrics
language:en
Short-container-title:Int J Gynecol Obstet

Author:

Lee Yoo-Young¹,Lee Jeong-Won²,Lu Lin³,Xu Wei³,Kollara Alexandra⁴,Brown Theodore⁴,Heo Eun-Jin⁵,May Taymaa¹

Affiliation:

1. Division of Gynecologic Oncology; Princess Margaret Cancer Centre; University Health Network; University of Toronto; Toronto ON Canada

2. Department of Obstetrics and Gynecology; Samsung Medical Center; Sungkyunkwan University School of Medicine; Seoul Korea

3. Department of Biostatistics; University Health Networks; Toronto ON Canada

4. Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Toronto ON Canada

5. Department of Obstetrics and Gynecology; Dankook University Hospital; Cheonan, Chungnam Korea

Funder

Mount Sinai Hospital/University Health Network Research Fund, Toronto

Publisher

Wiley

Subject

Obstetrics and Gynaecology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ijgo.12653/fullpdf

Reference25 articles.

1. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?;Chi;Gynecol Oncol,2006

2. Latest research and treatment of advanced-stage epithelial ovarian cancer;Coleman;Nat Rev Clin Oncol,2013

3. Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study;Garcia-Soto;Gynecol Oncol,2016

4. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: Analysis of prospective randomised phase III trials;Mahner;Eur J Cancer,2013

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk Prediction Model for Surgical Complications and Predictors of Delay/Omission of Adjuvant Chemotherapy Post Primary Cytoreduction in Epithelial Ovarian Cancer;Indian Journal of Surgery;2024-06-10

2. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery;Cochrane Database of Systematic Reviews;2022-09-26

3. Does timing of treatment have an effect on survival in ovarian carcinoma?;Journal of Basic and Clinical Health Sciences;2022-09-05

4. Where is ERAS in the management of advanced ovarian cancer?: between myths and truths;Journal of Gynecologic Oncology;2022

5. The impact of interval between primary cytoreductive surgery with bowel resection and initiation of adjuvant chemotherapy on survival of women with advanced ovarian cancer: a multicenter cohort study;Journal of Gynecologic Oncology;2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3